These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
72 related articles for article (PubMed ID: 20091169)
1. A phase I dose escalation and pharmacokinetic study of vatalanib (PTK787/ZK 222584) in combination with paclitaxel in patients with advanced solid tumors. Chiorean EG; Malireddy S; Younger AE; Jones DR; Waddell MJ; Sloop MI; Yu M; Hall SD; Schneider B; Sweeney CJ Cancer Chemother Pharmacol; 2010 Aug; 66(3):441-8. PubMed ID: 20091169 [TBL] [Abstract][Full Text] [Related]
2. A phase IA, open-label, dose-escalating study of PTK787/ZK 222584 administered orally on a continuous dosing schedule in patients with advanced cancer. Drevs J; Medinger M; Mross K; Fuxius S; Hennig J; Buechert M; Thomas A; Unger C; Chen BL; Lebwohl D; Laurent D Anticancer Res; 2010 Jun; 30(6):2335-9. PubMed ID: 20651389 [TBL] [Abstract][Full Text] [Related]
3. Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours. Mross K; Drevs J; Müller M; Medinger M; Marmé D; Hennig J; Morgan B; Lebwohl D; Masson E; Ho YY; Günther C; Laurent D; Unger C Eur J Cancer; 2005 Jun; 41(9):1291-9. PubMed ID: 15939265 [TBL] [Abstract][Full Text] [Related]
4. Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer. Thomas AL; Morgan B; Horsfield MA; Higginson A; Kay A; Lee L; Masson E; Puccio-Pick M; Laurent D; Steward WP J Clin Oncol; 2005 Jun; 23(18):4162-71. PubMed ID: 15867205 [TBL] [Abstract][Full Text] [Related]
5. Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome. Roboz GJ; Giles FJ; List AF; Cortes JE; Carlin R; Kowalski M; Bilic S; Masson E; Rosamilia M; Schuster MW; Laurent D; Feldman EJ Leukemia; 2006 Jun; 20(6):952-7. PubMed ID: 16617323 [TBL] [Abstract][Full Text] [Related]
6. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. Morgan B; Thomas AL; Drevs J; Hennig J; Buchert M; Jivan A; Horsfield MA; Mross K; Ball HA; Lee L; Mietlowski W; Fuxuis S; Unger C; O'Byrne K; Henry A; Cherryman GR; Laurent D; Dugan M; Marmé D; Steward WP J Clin Oncol; 2003 Nov; 21(21):3955-64. PubMed ID: 14517187 [TBL] [Abstract][Full Text] [Related]
7. A phase I trial to determine the safety of imatinib in combination with vatalanib in patients with advanced malignancies. Spigel D; Jones S; Hainsworth J; Infante J; Greco FA; Thompson D; Doss H; Burris H Cancer Invest; 2011 May; 29(4):308-12. PubMed ID: 21469980 [TBL] [Abstract][Full Text] [Related]
8. A phase I/IIA trial of continuous five-day infusion of squalamine lactate (MSI-1256F) plus carboplatin and paclitaxel in patients with advanced non-small cell lung cancer. Herbst RS; Hammond LA; Carbone DP; Tran HT; Holroyd KJ; Desai A; Williams JI; Bekele BN; Hait H; Allgood V; Solomon S; Schiller JH Clin Cancer Res; 2003 Sep; 9(11):4108-15. PubMed ID: 14519633 [TBL] [Abstract][Full Text] [Related]
9. Phase I evaluation of continuous 5-fluorouracil infusion followed by weekly paclitaxel in patients with advanced or recurrent gastric cancer. Kondo K; Kobayashi M; Kojima H; Hirabayashi N; Kataoka M; Araki K; Matsui T; Takiyama W; Miyashita Y; Nakazato H; Nakao A; Sakamoto J Jpn J Clin Oncol; 2005 Jun; 35(6):332-7. PubMed ID: 15961435 [TBL] [Abstract][Full Text] [Related]
10. Phase I clinical trial of STA-4783 in combination with paclitaxel in patients with refractory solid tumors. Berkenblit A; Eder JP; Ryan DP; Seiden MV; Tatsuta N; Sherman ML; Dahl TA; Dezube BJ; Supko JG Clin Cancer Res; 2007 Jan; 13(2 Pt 1):584-90. PubMed ID: 17255281 [TBL] [Abstract][Full Text] [Related]
11. A phase IB, open-label dose-escalating study of the oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK), in combination with FOLFOX4 chemotherapy in patients with advanced colorectal cancer. Thomas AL; Trarbach T; Bartel C; Laurent D; Henry A; Poethig M; Wang J; Masson E; Steward W; Vanhoefer U; Wiedenmann B Ann Oncol; 2007 Apr; 18(4):782-8. PubMed ID: 17218488 [TBL] [Abstract][Full Text] [Related]
12. Phase I/II trial of combination therapy with S-1 and weekly paclitaxel in patients with unresectable or recurrent gastric cancer. Inada S; Tomidokoro T; Fukunari H; Sato T; Hatano T; Nishimura A; Kawauchi Y; Nikkuni K; Shimizu T; Sato T; Yanagi M; Takahashi S; Yoshida H; Sugita M; Hayashi T Cancer Chemother Pharmacol; 2009 Jan; 63(2):267-73. PubMed ID: 18379784 [TBL] [Abstract][Full Text] [Related]
13. A phase I trial of carboxyamido-triazole and paclitaxel for relapsed solid tumors: potential efficacy of the combination and demonstration of pharmacokinetic interaction. Kohn EC; Reed E; Sarosy GA; Minasian L; Bauer KS; Bostick-Bruton F; Kulpa V; Fuse E; Tompkins A; Noone M; Goldspiel B; Pluda J; Figg WD; Liotta LA Clin Cancer Res; 2001 Jun; 7(6):1600-9. PubMed ID: 11410496 [TBL] [Abstract][Full Text] [Related]
14. Phase I study of escalating doses of edatrexate in combination with paclitaxel in patients with metastatic breast cancer. D'Andrea G; Fennelly D; Norton L; Baselga J; Gilewski T; Hudis C; Moynahan ME; Raptis G; Sklarin N; Surbone A; Theodoulou M; Templeton MA; Yao TJ; Seidman AD Clin Cancer Res; 1999 Feb; 5(2):275-9. PubMed ID: 10037175 [TBL] [Abstract][Full Text] [Related]
15. A phase I trial of intravenous melphalan, paclitaxel, and cisplatin plus granulocyte-colony stimulating factor in patients with suboptimal advanced epithelial ovarian carcinoma or peritoneal carcinoma. Gershenson DM; Morris M; Burke TW; Levenback C; Wolf J; Lee JJ; Thall PF; Atkinson EN; Silva EG; Wharton JT Cancer; 1999 Dec; 86(11):2291-300. PubMed ID: 10590370 [TBL] [Abstract][Full Text] [Related]
16. Phase I/II study of DHA-paclitaxel in combination with carboplatin in patients with advanced malignant solid tumours. Harries M; O'Donnell A; Scurr M; Reade S; Cole C; Judson I; Greystoke A; Twelves C; Kaye S Br J Cancer; 2004 Nov; 91(9):1651-5. PubMed ID: 15494716 [TBL] [Abstract][Full Text] [Related]
17. Aggressive simultaneous radiochemotherapy with cisplatin and paclitaxel in combination with accelerated hyperfractionated radiotherapy in locally advanced head and neck tumors. Results of a phase I-II trial. Kuhnt T; Becker A; Pigorsch S; Pelz T; Bloching M; Passmann M; Lotterer E; Hänsgen G; Dunst J Strahlenther Onkol; 2003 Oct; 179(10):673-81. PubMed ID: 14566475 [TBL] [Abstract][Full Text] [Related]
18. A phase I and pharmacokinetic study of paclitaxel poliglumex and cisplatin in patients with advanced solid tumors. Verschraegen CF; Skubitz K; Daud A; Kudelka AP; Rabinowitz I; Allievi C; Eisenfeld A; Singer JW; Oldham FB Cancer Chemother Pharmacol; 2009 Apr; 63(5):903-10. PubMed ID: 18682950 [TBL] [Abstract][Full Text] [Related]
19. A phase I and pharmacokinetic study of losoxantrone and paclitaxel in patients with advanced solid tumors. Diab SG; Baker SD; Joshi A; Burris HA; Cobb PW; Villalona-Calero MA; Eckhardt SG; Weiss GR; Rodriguez GI; Drengler R; Kraynak M; Hammond L; Finizio M; Von Hoff DD; Rowinsky EK Clin Cancer Res; 1999 Feb; 5(2):299-308. PubMed ID: 10037178 [TBL] [Abstract][Full Text] [Related]